Nido Biosciences
Nido Biosciences was a neuroscience biotech developing precision medicines for debilitating neurological diseases. It emerged from stealth in 2023 with $109 million already raised and a lead drug candidate targeting spinal and bulbar muscular atrophy, also known as Kennedy's disease.
The Story
Nido was founded through 5AM Ventures' 4:59 Initiative, an internal program designed to incubate new biotech companies.
The startup focused on an area where the need was enormous: neurological diseases.
Its strategy was based on human genetics.
The idea was that better understanding the genetic mechanisms behind neurological diseases could reveal targets for precision medicines.
Nido's lead program was NIDO-361, a drug candidate aimed at spinal and bulbar muscular atrophy, a rare inherited disease that causes progressive muscle weakness.
The company emerged from stealth in May 2023 with an unusually large amount of capital already behind it.
Nido announced that it had raised $109 million across seed, Series A and Series B financing. Its investors included 5AM Ventures, Abingworth, Bessemer Venture Partners, Eli Lilly and Bioluminescence Ventures.
The funding gave Nido the runway to move its lead drug into clinical testing.
The Phase 2 trial was designed to evaluate the safety, tolerability and efficacy of NIDO-361 in patients with SBMA.
The study eventually completed.
But the results were not what the company had hoped for.
The Turning Point
In its shutdown announcement, Nido's CEO said the Phase 2 results meant NIDO-361 would no longer be considered a clinical candidate.
The company subsequently decided to close operations in early 2026.
This is a very different kind of startup failure from a consumer company running out of users.
Nido had significant funding.
It had experienced investors.
It had a clearly defined medical problem.
And it had successfully progressed a drug into a Phase 2 trial.
But biotechnology ultimately has a binary constraint: the drug has to demonstrate enough benefit to justify the next stage of development.
When the lead candidate failed to deliver sufficient benefit, the value of the remaining company collapsed.
The clinical trial is recorded as completed, with the trial record updated in March 2026.
Timeline
Funding
Nido Biosciences raised $109M in total capital across its operating history. Operating for 8 years in the Biotechnology / Neurology sector in United States, capital intensity and runway constraints played a defining role in its closure.
Why It Failed
Lead drug candidate failed to show sufficient benefit in Phase 2, leaving no viable path forward
When the primary growth hypothesis or strategic acquisition discussions stalled, the business lacked the financial buffer to pivot or restructure on its own terms.
Operating in Biotechnology / Neurology created structural dependencies that left no room for extended clinical, distribution, or revenue delays.
Lessons for Builders
“In biotech, years of work and hundreds of millions of dollars can ultimately depend on one clinical result. A failed lead program can erase the company's only credible path forward.”